Literature DB >> 22559218

Effect of nitric oxide inhibition on blood pressure and renal sodium handling: a dose-response study in healthy man.

Thomas Larsen1, Frank Holden Mose, Jesper Noergaard Bech, Erling Bjerregaard Pedersen.   

Abstract

Nitric oxide (NO) is a ubiquitous vasodilator and an important regulator of renal sodium excretion. To further investigate the role of NO in renal sodium handling, we studied the effects of the NO synthase inhibitor, NG-monomethyl-L-arginine (L-NMMA), in a crossover dose-response study. During NO inhibition mean arterial pressure increased dose-dependently and reached a plateau after 20 minutes of infusion. On the contrary, the fractional excretion of sodium was reduced equally in all three L-NMMA doses. This indicates that sodium excretion is highly sensitive to even small changes in renal NO bioavailability in healthy human.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22559218     DOI: 10.3109/10641963.2012.681727

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  8 in total

1.  Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.

Authors:  Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen
Journal:  Br J Clin Pharmacol       Date:  2015-06-05       Impact factor: 4.335

2.  Evaluation of Association Studies and Meta-Analyses of eNOS Polymorphisms in Type 2 Diabetes Mellitus Risk.

Authors:  Di Wang; Liangshu Liu; Chengyu Zhang; Wensheng Lu; Feifei Wu; Xiaofeng He
Journal:  Front Genet       Date:  2022-06-27       Impact factor: 4.772

3.  Effects of atorvastatin on systemic and renal NO dependency in patients with non-diabetic stage II-III chronic kidney disease.

Authors:  Frank Holden Mose; Thomas Larsen; Janni Majgaard Jensen; Annebirthe Bo Hansen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  Br J Clin Pharmacol       Date:  2014-10       Impact factor: 4.335

4.  Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: a randomized placebo-controlled trial.

Authors:  Thomas Larsen; Frank H Mose; Jesper N Bech; Erling B Pedersen
Journal:  BMC Nephrol       Date:  2013-07-26       Impact factor: 2.388

5.  Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study.

Authors:  Safa Al Therwani; My Emma Sofie Malmberg; Jeppe Bakkestroem Rosenbaek; Jesper Noergaard Bech; Erling Bjerregaard Pedersen
Journal:  BMC Nephrol       Date:  2017-08-15       Impact factor: 2.388

6.  Effect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects.

Authors:  Safa Al Therwani; Frank Holden Mose; Janni Majgaard Jensen; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  BMC Nephrol       Date:  2014-06-25       Impact factor: 2.388

7.  Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjects.

Authors:  Safa Al Therwani; Jeppe Bakkestrøm Rosenbæk; Frank Holden Mose; Jesper Nørgaard Bech; Erling Bjerregaard Pedersen
Journal:  BMC Nephrol       Date:  2017-03-13       Impact factor: 2.388

8.  The effect of sodium nitrite infusion on renal function, brachial and central blood pressure during enzyme inhibition by allopurinol, enalapril or acetazolamide in healthy subjects: a randomized, double-blinded, placebo-controlled, crossover study.

Authors:  Jeppe B Rosenbaek; Erling B Pedersen; Jesper N Bech
Journal:  BMC Nephrol       Date:  2018-09-21       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.